Clinicopathological study of glomerular diseases associated with sarcoidosis : A multicenter study. by Stehlé, Thomas et al.
Clinicopathological study of glomerular diseases
associated with sarcoidosis : A multicenter study.
Thomas Stehle´, Dominique Joly, Philippe Vanhille, Jean-Jacques Boffa,
Philippe Re´my, Laurent Mesnard, Maxime Hoffmann, Philippe Grimbert,
Gabriel Choukroun, Franc¸ois Vrtovsnik, et al.
To cite this version:
Thomas Stehle´, Dominique Joly, Philippe Vanhille, Jean-Jacques Boffa, Philippe Re´my, et al..
Clinicopathological study of glomerular diseases associated with sarcoidosis : A multicenter
study.. Orphanet Journal of Rare Diseases, BioMed Central, 2013, 8 (1), pp.65. <10.1186/1750-
1172-8-65>. <inserm-00823377>
HAL Id: inserm-00823377
http://www.hal.inserm.fr/inserm-00823377
Submitted on 16 May 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH Open Access
Clinicopathological study of glomerular diseases
associated with sarcoidosis: a multicenter study
Thomas Stehlé1, Dominique Joly2, Philippe Vanhille3, Jean-Jacques Boffa4, Philippe Rémy1, Laurent Mesnard5,
Maxime Hoffmann6, Philippe Grimbert1, Gabriel Choukroun7, François Vrtovsnik8, Jérôme Verine9,
Dominique Desvaux10, Francine Walker11, Philippe Lang1, Matthieu Mahevas12, Dil Sahali1 and Vincent Audard1*
Abstract
Background: The association between sarcoidosis and glomerular diseases has not been extensively investigated in
a large series and the potential features of this uncommon association remain to be determined.
Methods: We retrospectively identified 26 patients with biopsy-proven glomerular lesions that occurred in a
sarcoidosis context. Potential remission of glomerular disease and sarcoidosis under specific treatment (steroid
and/or immunosuppressive agents) was recorded for all patients. Demographic, clinical and biological characteristics
were assessed at the time of kidney biopsy for each patient. Therapeutic data were analyzed for all patients.
Results: Glomerular disease occurred after the diagnosis of sarcoidosis in 11 of 26 cases (42%) (mean delay of
9.7 years). In six patients (23%), the glomerulopathy preceded the sarcoidosis diagnosis (mean delay 8 years). In the last
nine patients (35%), both conditions occurred simultaneously. The most frequent glomerular disease occurring in
sarcoidosis patients was membranous nephropathy in eleven cases. Other glomerular lesions included IgA
nephropathy in six cases, focal segmental glomerulosclerosis in four patients, minimal change nephrotic syndrome for
three patients and proliferative lupus nephritis in two patients. Granulomatous interstitial nephritis was associated with
glomerular disease in six patients and was exclusively found in patients in whom the both disease occurred
simultaneously. In nine patients with simultaneous glomerular and sarcoidosis diseases, we observed a strong
dissociation between glomerular disease and sarcoidosis in terms of steroid responsiveness. At the end of the
follow-up (mean of 8.4 years), six patients had reached end-stage renal disease and three patients had died.
Conclusions: A wide spectrum of glomerular lesions is associated with sarcoidosis. The close temporal relationship
observed in some patients suggests common causative molecular mechanisms of glomerular injury but complete
remission of both diseases in response to exclusive steroid therapy is infrequent.
Keywords: Nephrotic syndrome, Glomerular disease, Kidney biopsy, Sarcoidosis
Background
Sarcoidosis is a chronic multisystemic inflammatory dis-
ease of unknown origin, characterized by the presence of
non-caseating, epitheliod granulomas in some tissues
leading to organ dysfunction [1,2]. Sarcoidosis typically
affects young adults and its clinical course ranges from
spontaneous resolution to chronic progressive disease.
The severity and diversity of the clinical manifestations
related to sarcoidosis depend on the extent of the infil-
trating granulomatous lesions, which preferentially in-
volve the lower respiratory tract. Granulomatous lesions
can also affect extrapulmonary sites, such as the lymph
nodes, heart, kidneys, central nervous system, liver, spleen,
larynx and eyes [2,3]. Pathophysiological mechanisms
involved in the formation, maintenance or spontaneous
resolution of sarcoidosis granuloma thought to be linked
to genetic susceptibility and to unidentified environmental
antigens which trigger an uncontrolled cell-mediated im-
mune reaction involving macrophages and CD4 type 1
helper T (Th1) cells [2,4,5].
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The prevalence of kidney impairment in sarcoidosis pa-
tients ranges from 10% to 20% of cases [6]. Renal injury is
most commonly due to disorders in calcium homeostasis,
with renal stone disease and nephrocalcinosis [6]. Granu-
lomatous tubulointerstitial nephritis (GTIN) is a less com-
mon cause of renal lesions that occurs in approximately
20% of patients with sarcoidosis [7], and benefits from
steroid therapy [8,9]. By contrast, glomerular diseases
have been rarely reported in patients with sarcoidosis
[6]. Most publications reporting glomerular diseases in
the context of sarcoidosis consisted exclusively in case
reports. The nature of glomerular lesions seems to be
diverse, with membranous nephropathy (MN) [10-14]; min-
imal change nephrotic syndrome (MCNS) [15-17]; focal seg-
mental glomerulosclerosis (FSGS) [18-20], imunoglobulin
A nephropathy (IgAN) [21-24] and proliferative glomer-
ulonephritis [13,25,26].
To our knowledge no extensive study has been per-
formed to describe the spectrum of glomerular diseases
that occurs in the context of sarcoidosis. In this study,
we retrospectively identified 26 patients with biopsy-
proven glomerular disease and sarcoidosis and further
analyzed the clinical, histological, laboratory, and thera-
peutic data of these patients to assess the significance of
this rare association.
Methods
Patients
Twenty-six patients suffering from both sarcoidosis
and glomerular disease were retrospectively identified
and followed between 1977 and 2012 in the Nephrology
Departments of seven French hospitals (Henri Mondor
Hospital, Necker Hospital, Valenciennes Hospital, Tenon
Hospital, La Louvière Hospital, Amiens Hospital, Bichat
Hospital). We conducted this retrospective study by
sending a questionnaire to all nephrology departments
involved in the management of glomerular diseases to
determine if some patients exhibited glomerular in-
volvement in the context of sarcoidosis occurrence. In
each hospital, patients were identified by computing of
the renal pathology and clinical diagnosis databases. All
patients underwent a renal biopsy for the exploration of
proteinuria and/or renal impairment. Demographic,
clinical and laboratory data were assessed for each pa-
tient at the time of kidney biopsy. Glomerular kidney
disease was considered as occurring simultaneously with
sarcoidosis when the delay between the diagnoses of both
diseases was less than three months. Follow up data
(at least six months after kidney biopsy) were obtained
for all patients.
Sarcoidosis diagnosis
Sarcoidosis was diagnosed according to the statement of
the American Thoracic Society, the European Respiratory
Society and the World Association of Sarcoidosis [27].
Its diagnosis was supported by a body of evidence in-
cluding, clinical, biological, radiographic findings and/
or histological evidence of non-caseating granulomas on
tissue biopsy [1,2,5]. The number of affected organs was
systematically reviewed for all patients. In patients with
lung involvement, the four-stage radiographic classifica-
tion of sarcoidosis was used to determine the severity of
the pulmonary lesions associated with sarcoidosis: stage
1 for bilateral hilar lymphadenopathy; stage 2 for pulmon-
ary infiltrates associated with intrathoracic adenopathies;
stage 3 for isolated parenchymal infiltration without fi-
brosis; and stage 4 consisted of pulmonary fibrosis [28].
Sarcoidosis therapy, including steroid and/or immunosup-
preseive agents use was recorded for all patients.
Glomerular disease diagnosis
Chronic kidney disease was defined as a permanently
(lasting at least three months) decrease of estimated
glomerular filtration rate (eGFR) of less than 60 ml/min/
1.73 m2 according to the modification of diet in renal
disease (MDRD) formula [29]. Proteinuria was defined
as an albumin excretion rate of > 0.3 g/d. Nephrotic syn-
drome was defined by urinary protein excretion rates of
more than 3 g/d and serum albumin excretion rates
below 30 g/L.
Diagnosis of MCNS included the presence of minimal
change glomerular lesions and the absence of immuno-
globulin and/or complement deposits [30]. FSGS lesions
were identified by the presence of segmentally collapsed
glomerular capillaries with areas of glomerular scarring
associated with focal and segmental granular deposition
of IgM and C3 within the segmental glomerular scler-
oses [31]. MN was characterized granular subepithelial
deposition of immunoglobulins and complement along
the basement membrane in IF study [32]. Diagnosis of
IgAN consisted of the presence of IgA-dominant or
codominant immune deposits within the mesangium
[33]. Patients who fulfilled the 1997 American College
of Rheumatology revised criteria for systemic lupus
erythematosus (SLE) with documented sarcoidois were
also included in this study [34]. In these cases, renal
pathological lesions of SLE were analyzed according to
the 2003 International Society of Nephrology and Renal
Pathology Society (ISN/RPS) classification [35].
For patients with a diagnosis of MN, MCNS or FSGS,
a proteinuria level of less than 0.3 g/d at the six-month
follow-up defined a complete remission. Patients with a
proteinuria level between 0.3 and 3 g/d and those whom
with at least 50% reduction in the level of proteinuria,
with an albumin level of > 30 g/L were considered to be
in partial remission. IgAN and lupus nephritis were
considered to be in remission when the proteinuria level
decreased (of more than 50% of initial proteinuria level)
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Table 1 Demographic, clinical and laboratory data of all patients with glomerular disease and sarcoidosis
Characteristics Overall population MN IgAN MCNS FSGS Lupus nephritis
Number of patients 26 11(42%) 6 (23%) 3 (12%) 4 (15%) 2 (8%)
Sex (women/men) 8/18 3/8 2/4 0/3 2/2 1/1
Mean age at sarcoidosis diagnosis (yrs) (range) 37 (19–56) 39 (19–52) 34 (22–37) 36 (29–54) 40 (28–56) 36 (35–37)
Mean age at GD diagnosis (yrs) (range) 39 (0.6-59) 40 (27–57) 38 (22–53) 29 (0.5-59) 47 (38–57) 39 (36–44)
Number of patients with both conditions occurring simultaneously (%) 9 (35%) 3 3 1 2 0
Number of patients with GD before sarcoidosis (%) 6 (23%) 5 0 1 0 0
Number of patients with GD after sarcoidosis (%) 11 (42%) 3 3 1 2 2
Mean number of organs affected by sarcoidosis (range) 2.6 (1–6) 2.3 (1–3) 3.2 (1–6) 2.7 (2–3) 2.3 (1–4) 3.5 (3–4)
Steroid therapy for sarcoidosis (n) 16 (61%) 5 4 2 3 2
Sarcoidosis controlled by steroid therapy 8 2 3 2 1 0
Steroid-dependent or -resistant sarcoidosis 8 3 1 0 2 2
Mean creatinine level (mg/dL) (range) 1.40 (0.68-3.42) 1.30 (0.68-2.99) 1.63 (0.68-2.41) 1.14 (1.02-1.27) 1.75 (1.05-3.42) 0.94 (0.84-1.04)
Mean GFR (ml/min/1.73 m2) (range) 70.7 (16–133) 79.2 (23–133) 60.9 (26–97) 77.1 (62–92) 51.2 (16–73) 86 (61–111)
Mean proteinuria level (g/d) (range) 5.7 (0.45-20) 7.4 (0.86-20) 5 (1–12) 3.3 (3–3.6) 4.5 (1.7-6.6) 0.7 (0.45-1)
Serum albumin (g/L) 25,9 (9.7-43) 24,3 (9.7-43) 31 (17–39) 22.3 (15–29) 23.5 (11.3-38) 38 (38–38)
Number of patients with NS 15 7 2 3 3 0
GTIN associated with GD (number) 6 2 2 1 1 0
Mean follow-up (months) 101 124 48 157 80 72
Remission of GD at the end of the follow-up
CR 9 4 2 1 1 1
PR 7 3 2 1 1 0
Mean GFR at the end of the follow-up (ml/min/1.73 m2) * 67.8 68.7 76.4 68.1 48.3 66.5
End-stage renal disease during follow-up 6 2 1 1 1 1
Death during the follow-up 3 1 1 0 1 0
MN: Membranous Nephropathy, IgAN: IgA nephropathy, MCNS: minimal change nephrotic syndrome, FSGS: focal and segmental glomerulosclerosis, GD: glomerular disease, GFR: glomerular filtration rate, NS: nephrotic
syndrome, GTIN: granulomatous tubulointerstitial nephritis, CR: complete remission, PR: partial remission.
* after exclusion of patients with end-stage renal disease.
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with the stabilization or improvement of GFR. Specific
treatment of glomerular disease (steroid and/or immuno-
suppressive treatment) was recorded for all patients.
Results
Clinical and biological data of patients with glomerular
disease and sarcoidosis
Twenty-six patients (18 men and 8 women) were retro-
spectively identified. Their demographic, clinical and bio-
logical data are summarized in Table 1. The mean ages at
the onset of the sarcoidosis and glomerular disease diag-
nosis were 37 years (range of 19–56 years) and 39 years
(range of six months-59 years), respectively. In 22 patients,
the diagnosis of sarcoidosis was confirmed by organ or
tissue biopsy. Pathological confirmation of the sarcoid-
osis diagnoses was based on lung biopsy (nine cases),
skin biopsy (three cases), lymph node biopsy (seven
cases), muscle biopsy (one case), peritoneal biopsy (one
case), and salivary glands biopsy (one case). In four pa-
tients, the diagnosis of sarcoidosis was based only on
compatible clinical, biological and radiographic presen-
tations [27].
Chest radiographs confirmed the stages of the sarcoid-
osis thoracic involvement in 22 patients: nine patients
had stage 1, ten patients had stage 2 and three patients
had stage 3. Extrathoracic localization (other than GTIN)
was present in 22 patients. The mean number of organs
affected by sarcoidosis was estimated to be 2.6.
Sarcoidosis was considered to be an indolent disease,
not requiring specific curative treatment in nine patients
(34%). One patient received exclusively topical steroid
therapy for localized uveitis. Sixteen patients (61%) re-
ceived systemic steroid therapy to control active, life-
threatening sarcoidosis. In eight patients, steroid therapy
led to complete remission of granulomatous disease.
Among the eight remaining patients, three developed
steroid-dependent sarcoidosis, which required prolonged
therapy, whereas five patients displayed steroid-resistant
sarcoidosis, which required immunosuppressive therapy
consisting of Azathioprine (two cases) or Plaquenil
(three cases).
Glomerular disease was diagnosed after sarcoidosis in
11 cases (42%) with a mean delay of 9.7 years (range ten
months to 20 years) between the two diagnoses (Table 1).
Sarcoidosis was considered to be in complete remission
at the time of renal biopsy in six of these patients,
whereas it was either: indolent and not treated in three
patients; resistant to steroid therapy in one patient; and
steroid-dependent in one patient. In six patients (23%),
the glomerulopathy preceded the diagnosis of sarcoid-
osis, with an average delay of eight years (range from
six months to 25 years) between the two diagnoses.
Nine patients (35%) simultaneously displayed glomerular
disease and sarcoidosis (Table 2). All of these patients
(except patient 2 [pt2]) received exclusive steroid ther-
apy to treat both conditions, regardless of the type of
glomerular lesions. With this therapeutic management,
sarcoidosis was considered to be in complete remission
in four cases (pt5, pt7, pt8 and pt9). In these patients,
effective treatment of sarcoidosis was associated with
complete remission of glomerular disease in only one
case (pt7) and with partial remission in three cases (pt5,
pt8 and pt9). In three other patients (pt1, pt3 and pt6),
steroid therapy led to complete remission of glomerular
disease but failed to induce remission of sarcoidosis. In
one patient (pt4), steroids failed to induce remission of
either glomerular disease or sarcoidosis.
The spectrum of glomerular lesions associated with
sarcoidosis consisted of MN in eleven patients (42%),
IgA nephropathy in six cases (23%), FSGS in four
patients (15%), MCNS for three patients (12%) and prolif-
erative lupus nephritis in two patients (8%). As showed
in Figure 1, MN seems to be more common in the con-
text of sarcoidosis than in general population (42% of
cases vs 10–15% of glomerular diseases in general popu-
lation) whereas incidence of other glomerular diseases
seems to be quite similar [36,37]. GTIN was observed in
association with glomerular injury in six patients (23%)
(Figures 2, 3A, 3B and 4). GTIN was exclusively present
in renal biopsy of patients exhibiting concomitantly sar-
coidosis and glomerular disease (Table 2). Mean pro-
teinuria level at the onset of renal involvement was
estimated to be 5.7 g/d (range of 0.45-20 g/d). Mean
GFR at the time of glomerular disease diagnosis was
70.7 mL/min/1.73 m2 (range of 16–133 ml/min per
1.73 m2). Nine patients displayed significant renal im-
pairment (GFR of < 60 ml/min/1.73 m2) at the time of
renal biopsy.
Membranous nephropathy
In our study, MN was the most frequent glomerular dis-
order associated with sarcoidosis (42% of cases). Among
these cases, one of them has been described previously
[14]. In this group, only three patients exhibited glom-
erular lesions simultaneously with sarcoidosis, whereas
MN preceded the onset of sarcoidosis in five patients
(mean delay of 4.5 years). In three other patients, MN
was diagnosed after sarcoidosis (mean delay of 12.6 years).
Mean proteinuria level was 7.4 g/d and the mean GFR
at the time of MN diagnosis was estimated to be
79.2 mL/min/1.73 m2. In two patients with simultan-
eous MN and sarcoidosis (pt1 and 9), the renal biopsy
revealed a typical GTIN pattern in association with
glomerular injury. In patient 1, steroid therapy induced
complete remission of MN, but did not induce remis-
sion of sarcoidosis until after Plaquenil treatment was
added to steroid therapy (Table 2).
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Table 2 Characteristics of the eight patients with sarcoidosis and glomerular disease occurring simultaneously
pt1 pt2 pt3 pt4 pt5 pt6 pt7 pt8 pt9
Type of GD MN MN FSGS FSGS IgAN IgAN IgAN MCNS MN
Age at GD diagnosis (years) 51.9 50.6 56.4 46.3 52.5 22.2 25.2 28.7 44
Proteinuria level (g/d) 1.8 4.3 1.7 6.6 1 1.3 1 3 7
GFR (ml/min/1.73 m2) 35 69 56 60 97 96 81 92 89
Serum Albumin (g/L) 43 31.6 38 27 17 35 38 29 16
GTIN (+ present -absent) + - + - + + - + +
Affected organs Lymph nodes
Erythema Nodosum
Spleen Lymph
nodes parotitis
Lung Skin Lung Lymp
nodes
Lung Lymph
nodes Liver
Spleen Bone
marrow Salivary glands
Lung Lymph
nodes Liver
Spleen parotidis
Lymph
nodes
Lymph nodes
Skin epididymitis
Lymph nodes
Salivary glands
Radiographic classification (stage) 1 0 2 2 3 1 1 1 1
Steroid treatment yes no yes yes yes yes yes yes yes
Remission of GD with steroids CR no CR no PR CR CR PR PR
Remission of sarcoidosis with steroids no no no no yes no yes yes yes
Other immunosuppressive treatment
(date of introduction)
Plaquenil (M7) Plaquenil
(M19)
Aza (M13) Aza (M18) MMF (M12)
Duration of follow-up (years) 9 0.6 2.7 5 0.6 3.3 10.8 2 0.6
GFR at the end of follow-up (mL/min/
1.73 m2)
56.8 67 died dialysis 86.6 120.4 78.1 80 72
GD: Glomerular disease, MN: membranous nephropathy, IgAN: IgA nephropathy, MCNS: minimal change nephrotic syndrome, FSGS: focal and segmental glomerulosclerosis, GTIN: granulomatous tubulointerstitial
nephritis, GFR: glomerular filtration rate, Aza: azathioprine, MMF: Mycophenolate Mofetil, CR: complete remission, PR: partial remission.
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IgA nephropathy
Among the six patients with biopsy-proven IgAN, three
of them presented with glomerular disease and sarcoid-
osis simultaneously. In three other patients, IgAN oc-
curred after sarcoidosis with a mean delay of 6.7 years.
The mean proteinuria level at presentation was 5 g/day.
The mean GFR of this subgroup of patients was estimated
at 60.9 mL/min/1.73 m2. All patients with simultaneous
sarcoidosis and IgAN (pt5, pt6 and pt7) received steroid
treatment, which led to complete remission of sarcoidosis
in two cases (pt 5 and pt7) (Table 2), whereas Azathioprin
treatment was required for uncontrolled sarcoidosis in
one patient (pt6). Steroid therapy induced complete remis-
sion of IgAN in two of these three cases (pt6 and pt7) and
partial remission in one case (pt5).
Focal segmental glomerulosclerosis
Four patients exhibited typical FSGS lesions on renal bi-
opsy. Renal function was significantly impaired (mean
GFR of 51.2 mL/min/1.73 m2) and the mean proteinuria
level was 4.5 g/d. Two patients were diagnosed with FSGS
and sarcoidosis simultaneously and two patients devel-
oped FSGS after sarcoidosis with delays of 7.3 years and
19.8 years. Typical GTIN lesions were also found in the
biopsy of one patient who had simultaneous FSGS and
sarcoidosis (pt3). Steroid therapy for this patient (pt3)
led to complete remission of proteinuria but did not
significantly improve sarcoidosis. In the second patient
with simultaneous FSGS and sarcoidosis (pt4), steroid
treatment failed to reduce proteinuria or to improve
sarcoidosis symptoms. Despite Azathioprin treatment,
sarcoidosis remained uncontrolled and the patient prog-
ressed to end-stage renal disease 3.7 years after initial
presentation.
Minimal change nephrotic syndrome
Three patients exhibited MCNS in the context of sar-
coidosis. In one case, both diseases developed simultan-
eously whereas one patient had MCNS 5 years after
sarcoidosis and one acquired it 25 years before the onset
of sarcoidosis. Nephrotic syndrome without significant
impairment of renal function was present in all patients
at the time of renal biopsy (mean GFR: 77.1 ml/min per
1.73 m2). GTIN was associated with MCNS lesions in
the patient with concomitant MCNS and sarcoidosis
(pt8). In this patient, steroid and mycophenolate mofetyl
therapies led to partial remission of the nephrotic syn-
drome, whereas sarcoidosis was considered to be in
complete remission after steroid therapy. The patient
who acquired MCNS before sarcoidosis had multiple
relapses of nephrotic syndrome and received several lines
of immunosuppressive treatment for steroid-dependent
MCNS. Unexpectedly, steroid and/or immunosuppressive
treatments were not administered at the time sarcoidosis
was diagnosed. Re-introduction of steroid therapy led to
sarcoidosis remission.
Lupus proliferative glomerulonephritis
Two patients with previous history of steroid-resistant
sarcoidosis had biopsy-proven lupus (SLE) glomerulo-
nephritis (class IIIA in one case and IIIA-V in the second
case). These patients developed sarcoidosis ten months
Figure 1 Incidence of glomerular diseases associated with
sarcoidosis compared to their distribution in general
population. A: Italian population, 11795 biopsies with glomerular
diseases among 13835 biopsies, from 1987 to 1993. B: American
population, 195 biopsies from 1974 to 2003. C: Study population,
from 1977 to 2012. MCNS: Minimal change nephrotic syndrome,
FSGS: Focal segmental glomerulosclerosis MN: Membranous
nephropathy, IgAN: IgA nephropathy.
Figure 2 Representative case of GTIN associated with MN (pt1)
(Masson’s trichrome staining). There is an epithelioid and giant
cell granuloma adjacent to apparently normal glomeruli. The IF
analysis revealed subepithelial granular deposits of IgG (data
not shown).
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and seven years, respectively, before the SLE diagnosis.
Renal biopsies were performed because of significant pro-
teinuria (1 g/d and 0.45 g/d, respectively) associated with
microscopic hematuria. Antinuclear antibodies were not
detected at the time sarcoidosis was diagnosed but became
evident when the renal manifestations began. Therapy for
lupus nephritis consisted of steroid and cyclophosphamide
drugs in both cases and led to complete remission in one
case, but failed to induce remission of lupus nephritis in
the second case.
Long-term clinical follow-up
Steroid and/or cytotoxic therapy was used to treat glom-
erular disease in 18 of 26 patients. Supportive treatment
was initiated in eight patients (five patients with MN,
two patients with IgAN and one patient with FSGS). At
the end of follow-up (average of 8.4 years), complete
remission of glomerular disease was confirmed in nine
patients, whereas remission was considered to be par-
tial for eight additional patients. Three other patients
displayed significant persistent proteinuria. Six patients
developed end-stage renal disease requiring intermit-
tent hemodialysis and three of them underwent kidney
transplantation. At the end of the follow-up, the mean
GFR after excluding the six patients with end stage renal
disease was estimated to be 67.8 mL/min per 1.73 m2 and
three patients died.
Discussion
In some sarcoidosis patients, the kidneys may be major
sites of inflammation and granuloma formation, which
leads to significant renal impairment [7]. In such cases,
it is likely that infiltration of activated T cells and macro-
phages into the interstitium results in granuloma forma-
tion and interstitial nephritis. Alternatively, in rare cases
of glomerular injury in the context of systemic sarcoid-
osis, the underlying molecular mechanisms of this asso-
ciation remain unclear. The aim of this retrospective was
not to determine the incidence and/or the prevalence of
glomerular involvement compared to interstitial neph-
ritis related to sarcoidosis but exclusively to describe
the spectrum of glomerular lesions observed in patients
with sarcoidosis.
Our study demonstrated that a wide spectrum of glom-
erular lesions may be found in sarcoidosis patients. As
these glomerular lesions do not share common patho-
physiological mechanisms, the existence of a direct mo-
lecular link between sarcoidosis and glomerular pathology
remains uncertain. Nevertheless, the close temporal rela-
tionship exhibited by nine patients, strongly suggests that
glomerular disease and sarcoidosis may be linked in these
patients.
Sarcoidosis is characterized by an infiltration of Th1
cells and macrophages into sites of inflammation and by
a dominant expression of Th1 cytokines with low levels
of Th2 cytokines [38,39]. Recent studies showed that sar-
coidosis is associated with an expansion of a regulatory T
cell subset with antiproliferative activity [40]. Most glom-
erular diseases found in patients with sarcoidosis are
thought to be caused by functional disorders of the im-
mune system. Compelling evidence suggests that primary
MCNS and FSGS with relapse also result from perturba-
tions of immune system [41]. Thus, we can postulate that
cytokines produced locally by granulomas may contribute
to alterations in the glomerular filtration barrier. Indeed,
increased production of TNF-alpha by granuloma macro-
phages and activated T cells has been reported [42]. Ex-
perimental observations suggest that TNF-alpha may
increase the permeability of the glomerular filtration
barrier [43]. In accord with previous observations, we
found that MN was the most frequent glomerular dis-
ease associated with sarcoidosis [6,10] and often
Figure 3 Granulomatous interstitial nephritis occurring
simultaneously with FSGS lesions (pt 3) (Masson’s trichrome
staining). A. An interstitial noncaseating epithelioid granuloma
associated with lymphocytes. Some tubulitis lesions are noted. B.
Typical FSGS lesion as a dense glomerular scar with adhesion
(synechia) to Bowman’s capsule surrounded by a halo and visceral
epithelial cell hyperplasia.
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preceded the sarcoidosis diagnosis. Sex ratio, mean age,
and proportion of patients with nephrotic syndrome in
patients with MN associated with sarcoidosis seem to
be similar to those in previous series of patients with
idiopathic membranous nephropathy [44-47]. The mo-
lecular link between these two conditions remains un-
clear since no target antigen or specific antibodies have
yet been identified. Circulating immune complexes
and hypergammaglobulinemia are a common finding
in sarcoidosis patients [27]. Recently, Knehtl et al. de-
scribed a patient with sarcoidosis and MN associated
with anti-phospholipase A2 receptor antibodies (anti-
PLA2R), suggesting that primary and secondary MN may
share certain pathophysiological processes [14]. Three
patients displayed IgAN simultaneously with active sar-
coidosis. This close temporal relationship strongly sug-
gests that immune dysregulation in sarcoidosis may lead
to IgA deposition in the glomerular mesangium. Indeed,
cytokine production may also play a critical role in the
production and glycosylation of systemic IgA leading to
IgAN [48]. The coexistence of SLE and sarcoidosis
seems to be a very rare finding [49] even if a recent
study suggests an increase of prevalence of SLE among
sarcoidosis patients [50]. Weinberg et al. showed that
the presence of anti-DNA antibodies in the serum of
sarcoidosis patients did not predict the subsequent
development of SLE [51]. We described here two in-
teresting cases of lupus nephritis occurring in steroid-
resistant sarcoidosis. In these two patients, we cannot
exclude the possibility of a fortuitous association without
known pathophysiologic relationship between both condi-
tions. Nevertheless, these two cases emphasize the need
to systematically screen sarcoidosis patients with renal
impairment for SLE antibodies.
Mahevas et al. have previously reported that GTIN
lesions occurred simultaneously with the first clinical
manifestations of sarcoidosis in 81% of these cases [8].
In our study, only nine patients (35%) displayed biopsy-
proven glomerular disease occurring simultaneously
with sarcoidosis. Our study demonstrated that all types
of glomerulopathies, except lupus nephritis, may be
identified in patients with a first relapse of sarcoidosis.
Among 11 patients with sarcoidosis that preceded the
diagnosis of glomerular disease, none displayed sarcoid-
osis relapse at the time of renal biopsy. Nevertheless,
three patients had untreated persistent sarcoidosis
and two others presented steroid-resistant or steroid-
dependent sarcoidosis. These five additional cases suggest
that persistent granuloma activity may secondarily pro-
mote the development of glomerular disease.
Regardless of the types of glomerular lesions found in
kidney biopsies, one major issue from our study was to
analyze the response to steroid therapy in patients with
glomerular diseases occurring simultaneously with sar-
coidosis. A recent survey conducted in 47 patients showed
that two criteria (the initial fibrotic score at renal biopsy
and the response after one month of steroid therapy) were
significantly associated with the renal prognosis of patients
with GTIN related to sarcoidosis [8]. In our study, exclu-
sive steroid therapy was administered to eight of the
nine patients with simultaneous glomerular disease and
sarcoidosis. Complete remission of both diseases oc-
curred in a single case (pt7) whereas partial remission
of the glomerulopathy and complete disappearance of
sarcoidosis related symptoms occurred in three patients
(pt5, pt8 and pt9). Despite steroid treatment, one pa-
tient (pt 4) displayed both persistent sarcoidosis and sig-
nificant proteinuria. Finally, we found that sarcoidosis
was frequently resistant to or dependent on steroid
treatment (4/8 patients). However, the failure of steroid
therapy to control sarcoidosis symptoms did not pre-
clude the remission of glomerular disease in three
patients (pt1, pt 3 and pt6). These observations are
different from those of existing case reports, in which glom-
erular disease activity appeared to be influenced by the re-
sponse of the sarcoidosis to steroid therapy [17,20,24,52].
Altogether, these observations show that the steroid re-
sponsiveness of sarcoidosis does not correlate with that of
glomerular disease and suggest that both diseases require
possibly a more aggressive therapy. Indeed, with a mean
follow-up of 101 months, six of the 26 patients (23%) had
chronic renal impairment requiring intermittent hemodial-
ysis and/or renal transplantation, although their mean
GFRs at the time of renal biopsy were not significantly
impaired. In contrast, among patients with isolated
GTIN who were followed for a median of 84 months,
Rajakariar et al. demonstrated that exclusive steroid
treatment may significantly improve GFR [9]. Similar
Figure 4 MCNS associated with GTIN (pt8) (Jones’ silver stain).
Diffuse granuloma infiltration composed of epithelioid and giant
cells throughout the interstitium without glomerular lesions in a
patient with nephrotic syndrome. The IF analysis was negative for all
analyzed glomeruli.
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results were found by Mahevas et al., suggesting that
glomerular lesions are less steroid-sensitive than inter-
stitial injury [8].
Conclusion
Our study showed that the spectrum of glomerular lesions
observed in the context of sarcoidosis is heterogeneous
and that only 35% of the patients displayed both diseases
simultaneously. For these cases, our study suggests that
exclusive steroid therapy is less efficient that previously
reported. Therefore, optimal therapeutic management can
only be determined after further investigations.
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